Literature DB >> 35138508

Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2.

Ismail Celik1, Abbas Khan2, Fenny Martha Dwivany3, Dong-Qing Wei2,4,5, Trina Ekawati Tallei6.   

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 continues to mutate. Numerous studies have indicated that this viral mutation, particularly in the receptor-binding domain area, may increase the viral affinity for human angiotensin-converting enzyme 2 (hACE2), the receptor for viral entry into host cells, thereby increasing viral virulence and transmission. In this study, we investigated the binding affinity of SARS-CoV-2 variants (Delta plus, Iota, Kappa, Mu, Lambda, and C.1.2) on hACE2 using computational modeling with a protein-protein docking approach. The simulation results indicated that there were differences in the interactions between the RBD and hACE2, including hydrogen bonding, salt bridge interactions, non-bonded interactions, and binding free energy differences among these variants. Molecular dynamics simulations revealed that mutations in the RBD increase the stability of the hACE2-spike protein complex relative to the wild type, following the global stability trend and increasing the binding affinity. The value of binding-free energy calculated using molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA) indicated that all mutations in the spike protein increased the contagiousness of SARS-CoV-2 variants. The findings of this study provide a foundation for developing effective interventions against these variants. Computational modeling elucidates that the spike protein of SARS-CoV-2 variants binds considerably stronger than the wild-type to hACE2.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  In Silico; Mutation; Receptor-binding domain; SARS-CoV-2; Spike; hACE

Year:  2022        PMID: 35138508     DOI: 10.1007/s11030-022-10392-x

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  51 in total

1.  Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.

Authors:  Timothée Bruel; Etienne Simon-Lorière; Felix A Rey; Olivier Schwartz; Delphine Planas; David Veyer; Artem Baidaliuk; Isabelle Staropoli; Florence Guivel-Benhassine; Maaran Michael Rajah; Cyril Planchais; Françoise Porrot; Nicolas Robillard; Julien Puech; Matthieu Prot; Floriane Gallais; Pierre Gantner; Aurélie Velay; Julien Le Guen; Najiby Kassis-Chikhani; Dhiaeddine Edriss; Laurent Belec; Aymeric Seve; Laura Courtellemont; Hélène Péré; Laurent Hocqueloux; Samira Fafi-Kremer; Thierry Prazuck; Hugo Mouquet
Journal:  Nature       Date:  2021-07-08       Impact factor: 49.962

2.  Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses.

Authors:  Saathvik R Kannan; Austin N Spratt; Alisha R Cohen; S Hasan Naqvi; Hitendra S Chand; Thomas P Quinn; Christian L Lorson; Siddappa N Byrareddy; Kamal Singh
Journal:  J Autoimmun       Date:  2021-08-11       Impact factor: 7.094

3.  Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.

Authors:  Zhuoming Liu; Laura A VanBlargan; Louis-Marie Bloyet; Paul W Rothlauf; Rita E Chen; Spencer Stumpf; Haiyan Zhao; John M Errico; Elitza S Theel; Mariel J Liebeskind; Brynn Alford; William J Buchser; Ali H Ellebedy; Daved H Fremont; Michael S Diamond; Sean P J Whelan
Journal:  Cell Host Microbe       Date:  2021-01-27       Impact factor: 31.316

4.  Mycena genomes resolve the evolution of fungal bioluminescence.

Authors:  Huei-Mien Ke; Hsin-Han Lee; Chan-Yi Ivy Lin; Yu-Ching Liu; Min R Lu; Jo-Wei Allison Hsieh; Chiung-Chih Chang; Pei-Hsuan Wu; Meiyeh Jade Lu; Jeng-Yi Li; Gaus Shang; Rita Jui-Hsien Lu; László G Nagy; Pao-Yang Chen; Hsiao-Wei Kao; Isheng Jason Tsai
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-23       Impact factor: 11.205

Review 5.  The variant gambit: COVID-19's next move.

Authors:  Jessica A Plante; Brooke M Mitchell; Kenneth S Plante; Kari Debbink; Scott C Weaver; Vineet D Menachery
Journal:  Cell Host Microbe       Date:  2021-03-01       Impact factor: 31.316

6.  Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.

Authors:  Wanbo Tai; Lei He; Xiujuan Zhang; Jing Pu; Denis Voronin; Shibo Jiang; Yusen Zhou; Lanying Du
Journal:  Cell Mol Immunol       Date:  2020-03-19       Impact factor: 11.530

7.  Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York.

Authors:  Medini K Annavajhala; Hiroshi Mohri; Pengfei Wang; Manoj Nair; Jason E Zucker; Zizhang Sheng; Angela Gomez-Simmonds; Anne L Kelley; Maya Tagliavia; Yaoxing Huang; Trevor Bedford; David D Ho; Anne-Catrin Uhlemann
Journal:  Nature       Date:  2021-08-24       Impact factor: 49.962

8.  Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.

Authors:  Jamie Lopez Bernal; Nick Andrews; Charlotte Gower; Eileen Gallagher; Ruth Simmons; Simon Thelwall; Julia Stowe; Elise Tessier; Natalie Groves; Gavin Dabrera; Richard Myers; Colin N J Campbell; Gayatri Amirthalingam; Matt Edmunds; Maria Zambon; Kevin E Brown; Susan Hopkins; Meera Chand; Mary Ramsay
Journal:  N Engl J Med       Date:  2021-07-21       Impact factor: 91.245

View more
  1 in total

1.  Prediction of infectivity of SARS-CoV2: Mathematical model with analysis of docking simulation for spike proteins and angiotensin-converting enzyme 2.

Authors:  Yutaka Takaoka; Aki Sugano; Yoshitomo Morinaga; Mika Ohta; Kenji Miura; Haruyuki Kataguchi; Minoru Kumaoka; Shigemi Kimura; Yoshimasa Maniwa
Journal:  Microb Risk Anal       Date:  2022-06-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.